Therapeutic potential of N,N-dimethyltryptamine in the treatment of psychiatric and neurodegenerative disorders
Jakub Schimmelpfennig, Kamila Jankowiak-Siuda
Pharmacotherapy in Psychiatry and Neurology 2023 DOI: 10.5114/fpn.2023.131979 (opens in new tab)
Study at a glance
AI-extracted from the abstractAbstract
AMA Schimmelpfennig J, Jankowiak-Siuda K. Therapeutic potential of N,N-dimethyltryptamine in the treatment of psychiatric and neurodegenerative disorders. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2023;39(2):115-130. doi:10.5114/fpn.2023.131979. APA Schimmelpfennig, J., & Jankowiak-Siuda, K. (2023). Therapeutic potential of N,N-dimethyltryptamine in the treatment of psychiatric and neurodegenerative disorders. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 39(2), 115-130. https://doi.org/10.5114/fpn.2023.131979 Chicago Schimmelpfennig, Jakub, and Kamila Jankowiak-Siuda. 2023. "Therapeutic potential of N,N-dimethyltryptamine in the treatment of psychiatric and neurodegenerative disorders". Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii 39 (2): 115-130. doi:10.5114/fpn.2023.131979. Harvard Schimmelpfennig, J., and Jankowiak-Siuda, K. (2023). Therapeutic potential of N,N-dimethyltryptamine in the treatment of psychiatric and neurodegenerative disorders. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 39(2), pp.115-130. https://doi.org/10.5114/fpn.2023.131979 MLA Schimmelpfennig, Jakub et al. "Therapeutic potential of N,N-dimethyltryptamine in the treatment of psychiatric and neurodegenerative disorders." Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, vol. 39, no. 2, 2023, pp. 115-130. doi:10.5114/fpn.2023.131979. Vancouver Schimmelpfennig J, Jankowiak-Siuda K. Therapeutic potential of N,N-dimethyltryptamine in the treatment of psychiatric and neurodegenerative disorders. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2023;39(2):115-130. doi:10.5114/fpn.2023.131979.
Comparable studies
Other narrative reviews on 5-MeO-DMT, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Neuropharmacology of N,N-dimethyltryptamine | 2016 | Review | |
| N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function Humans and animals (general) | 2018 | Review | |
| Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Humans (pharmacokinetics) | 2010 | Review | |
| Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT) | 2018 | Review | |
| A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. | 2013 | Review |
Citations in the library
Cites 46
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors Journal of Psychopharmacology October 11, 2017
- Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors Science February 16, 2023
- Neural correlates of the DMT experience assessed with multivariate EEG. Scientific Reports November 19, 2019
and 41 more in the library